CagriSema vs Tirzepatide — REDEFINE 4 Results

What Did REDEFINE 4 Show?

REDEFINE 4 was the first head-to-head trial comparing CagriSema against tirzepatide in people with obesity and at least one weight-related comorbidity. The 84-week open-label trial enrolled 809 participants and tested CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) against tirzepatide 15 mg, the highest approved dose of Eli Lilly’s dual agonist.

The primary endpoint was non-inferiority of CagriSema to tirzepatide for percentage weight change from baseline. Non-inferiority was not demonstrated. The treatment-regimen estimate — which includes all participants regardless of whether they completed treatment — showed 20.2% weight loss for CagriSema versus 23.6% for tirzepatide, a 3.4 percentage-point difference.

The on-treatment estimate — which only includes participants who stayed on treatment — narrowed the gap: 23.0% for CagriSema versus 25.5% for tirzepatide, a 2.5 percentage-point difference. Both analyses favored tirzepatide.

Safety profiles were broadly comparable across both treatment arms. Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — were the most commonly reported adverse events in both groups, consistent with the known GLP-1 class effect. Most events were mild to moderate in severity and tended to diminish over time.

Why Did CagriSema Fail the Primary Endpoint?

The REDEFINE 4 primary endpoint required CagriSema to demonstrate non-inferiority to tirzepatide — meaning the lower bound of the confidence interval for the treatment difference had to fall within a predefined margin. CagriSema’s 20.2% weight loss versus tirzepatide’s 23.6% produced a 3.4 percentage-point gap that exceeded this margin.

Several factors may have contributed to the outcome. The trial used an open-label design rather than a double-blind protocol. Participants and investigators knew which treatment was administered, which can introduce behavioral and expectation-related biases in both arms. Additionally, tirzepatide was tested at its maximum approved dose (15 mg), which represents its full efficacy ceiling in real-world use.

It is important to note that CagriSema still produced substantial absolute weight loss — over 20% — which exceeds the efficacy of most approved obesity treatments. The failure was relative: CagriSema could not match tirzepatide, but it remains a highly effective combination in its own right.

What Does This Mean for CagriSema Approval?

Novo Nordisk filed the CagriSema NDA on December 18, 2025 — before the REDEFINE 4 results were released. The filing was based primarily on the REDEFINE 1 trial, which showed 22.7% weight loss at 68 weeks versus placebo. The FDA decision is expected around October 2026.

A failed head-to-head trial against tirzepatide does not necessarily block FDA approval. CagriSema is not seeking approval on the basis of superiority or non-inferiority to tirzepatide. The FDA evaluates total evidence of safety and efficacy against placebo and the unmet medical need — not comparative positioning against a competitor drug.

That said, REDEFINE 4 data will be part of the review package and could factor into the FDA’s benefit-risk assessment. It also has significant commercial implications: if CagriSema cannot match tirzepatide on efficacy, Novo Nordisk’s marketing and pricing strategy for its next-generation obesity drug becomes more complex.

How Do the Mechanisms Differ?

CagriSema and tirzepatide target different receptor combinations, which underpins their different efficacy profiles:

CagriSema (Novo Nordisk) is a co-formulation of two separate molecules: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. The amylin component promotes satiety through a mechanism distinct from GLP-1, targeting the area postrema and other brainstem regions involved in appetite regulation. The combination hypothesis was that dual amylin + GLP-1 agonism would produce additive weight loss beyond either component alone.

Tirzepatide (Eli Lilly) is a single unimolecular dual agonist that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This differs from CagriSema’s co-formulation approach — tirzepatide is one molecule with dual activity, not two molecules combined. The GIP component appears to enhance fat metabolism and may contribute additional weight-loss mechanisms beyond GLP-1 agonism alone.

The REDEFINE 4 results suggest that, at least in this 84-week comparison, the GIP + GLP-1 approach produced greater weight loss than the amylin + GLP-1 combination. Whether this reflects a fundamental mechanistic advantage or is influenced by dosing, titration schedules, and trial design remains an open question.

What Should Researchers Watch Next?

1. FDA review of CagriSema NDA. The FDA decision is expected around October 2026. The agency will review the full REDEFINE clinical program — including REDEFINE 1 placebo-controlled data — alongside the REDEFINE 4 head-to-head results. Whether the failed comparator trial influences the regulatory decision or labeling language is a key watch point.

2. Novo Nordisk’s strategic response. REDEFINE 4 is a significant competitive setback for Novo Nordisk. How the company positions CagriSema commercially — particularly its messaging around the amylin + GLP-1 mechanism and potential differentiation beyond weight loss — will shape market reception if the drug is approved.

3. Triple-agonist data. The obesity pipeline extends beyond dual-mechanism drugs. Retatrutide (Eli Lilly), a triple GLP-1/GIP/glucagon receptor agonist, showed 24.2% weight loss at 48 weeks in Phase 2 and has Phase 3 trials underway. For the full three-way comparison, see Retatrutide vs Tirzepatide vs CagriSema. Triple agonism may represent the next frontier in weight-loss efficacy.

4. Commercial dynamics. Tirzepatide (Zepbound) is already commercially available and growing rapidly. CagriSema enters a market where the efficacy bar has been set high. The REDEFINE 4 data will factor into payer coverage decisions, formulary positioning, and prescriber preferences.

5. Long-term and cardiovascular outcome data. Both drugs have ongoing trials investigating cardiovascular outcomes, long-term safety, and weight-loss maintenance. These readouts will be critical for establishing the full clinical value proposition of each compound. Beyond efficacy, side effect profiles differ across GLP-1 agents — see our Ozempic vs Mounjaro vs Wegovy side effects comparison. For verified research peptide suppliers, see our best research peptides 2026 guide.